FEBS openbio



Prediction of target genes for miR-140-5p in pulmonary arterial hypertension using bioinformatics methods

Fangwei Li¹, Wenhua Shi¹, Yixin Wan², Qingting Wang¹, Wei Feng¹, Xin Yan¹, Jian Wang¹, Limin Chai¹, Qianqian Zhang¹ and Manxiang Li¹

1 Department of Respiratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, China

2 Department of Respiratory Medicine, Lanzhou University Second Hospital, China

Keywords

GO; KEGG; miR-140-5p; target gene; transcription factor

Correspondence

M. Li, Department of Respiratory Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277, West Yanta Road, Xi'an710061 Shaanxi, China Tel: +86-029-85324053 E-mail: manxiangli@hotmail.com

(Received 23 June 2017, revised 28 August 2017, accepted 15 September 2017)

doi:10.1002/2211-5463.12322

The expression of microRNA (miR)-140-5p is known to be reduced in both pulmonary arterial hypertension (PAH) patients and monocrotalineinduced PAH models in rat. Identification of target genes for miR-140-5p with bioinformatics analysis may reveal new pathways and connections in PAH. This study aimed to explore downstream target genes and relevant signaling pathways regulated by miR-140-5p to provide theoretical evidences for further researches on role of miR-140-5p in PAH. Multiple downstream target genes and upstream transcription factors (TFs) of miR-140-5p were predicted in the analysis. Gene ontology (GO) enrichment analysis indicated that downstream target genes of miR-140-5p were enriched in many biological processes, such as biological regulation, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathways. Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis found that downstream target genes were mainly located in Notch, TGF-beta, PI3K/Akt, and Hippo signaling pathway. According to TF-miRNA-mRNA network, the important downstream target genes of miR-140-5p were PPI, TGF-betaR1, smad4, JAG1, ADAM10, FGF9, PDGFRA, VEGFA, LAMC1, TLR4, and CREB. After thoroughly reviewing published literature, we found that 23 target genes and seven signaling pathways were truly inhibited by miR-140-5p in various tissues or cells; most of these verified targets were in accordance with our present prediction. Other predicted targets still need further verification in vivo and in vitro.

Pulmonary arterial hypertension (PAH) is a chronic progressive disease of pulmonary vasculature characterized by sustained elevation of pulmonary vascular resistance and pulmonary arterial pressure, consequently leading to right heart failure and eventual death [1]. The pathogenesis of PAH is associated with genetic predisposition, inflammation, increase in vascular tone, elevation in pulmonary artery cell proliferation and resistance to apoptosis, and the presence of *in situ* thrombosis [2–5]. Effect of current treatment on PAH remains poor and available therapies to improve long-term prognosis are limited [6], so exploring novel molecular mechanisms and generating therapeutic approaches are urgently needed.MicroRNAs (miR-NAs) are small noncoding RNA molecules around 22 nucleotides long that bind the 3'-untranslated region (UTR) of mRNA to degrade mRNA and therefore to negatively regulate relevant genes expression [7].

Abbreviations

GO, gene ontology; KEGG, kyoto encyclopedia of genes and genome; PAH, pulmonary arterial hypertension; PASMC, pulmonary arterial smooth muscle cell; TF, transcription factor.

miRNAs have the ability to target numerous genes mRNA, therefore potentially controlling a host of genes expression and the activity of multiple signaling pathways [8-10]. Recent studies have shown that reduction in microRNA (miR)-140-5p is found in both patients with PAH and monocrotaline-induced PAH models in rat, which is involved in the development of PAH [11,12]. Therefore, it is important to identify comprehensive downstream targets of miR-140-5p with bioinformatics analysis in PAH, and this might provide some critical information for the development and treatment of PAH. In this study, downstream target genes regulated by miR-140-5p and upstream transcription factors (TFs) regulating miR-140-5p expression were predicted, and the downstream target genes were analyzed for gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway. Next, the upstream TFs and downstream targets of miR-140-5p were determined according to the TF-miRNA-mRNA network. Finally, the direct downstream targets and relevant signaling pathways regulated by miR-140-5p were obtained in published literature and were compared with the predicted results of this study.

Materials and methods

Mature sequences of miR-140-5p in various species

Mature sequences of miR-140-5p in various species were obtained in the miRBase database (http://mirba se.org/index.shtml).

Target gene prediction of miR-140-5p

Identification of target genes is critical for characterizing the functions of miRNAs. In this study, miRanda (http://www.microrna.org/), TargetScan (http://www.ta rgetscan.org/), RNAhybrid (https://bibiserv.cebitec.unibielefeld.de/rnahybrid/submission.html), and miRDB (http://www.mirdb.org/) databases were used to predict the target genes of miR-140-5p. To make our predicted target genes more convincible, only the target genes predicted by at least three databases were selected for further analyses.

Database-based GO and KEGG pathway enrichment analysis

Target mRNA of miR-140-5p supported by at least three databases were used for GO analysis to predict gene functions. Integration Discovery (DAVID) software, version 6.7 (http://david.abcC.ncifcrf.gov), was used to perform GO analysis to identify biological processes, cellular components, and molecular functions of these target genes. At the same time, the probable signaling pathways in which these target genes were enriched were analyzed by KEGG database (http://www.genome.jp/kegg/). The *P*-value <0.05 was considered significant.

Upstream TFs prediction of miR-140-5p

Human miR-140-5p precursor was obtained in the miRBase database and its 5000 bp upstream was defined as the miR-140-5p promoter. The TFs of miR-140-5p were predicted using MOODS-python software (version 1.9.3) in JASPAR database (http://jaspar.binf. ku.dk/), which includes various vertebrate TFs. The *P*-value <0.0001 was considered significant.

Construction of the network for TF-miR-140-5p-mRNA

By merging the regulatory relationships between TFs and miR-140-5p, miR-140-5p and target genes, genes and genes (TF \rightarrow miRNA, miRNA \rightarrow gene and gene \rightarrow gene), we constructed a comprehensive TF–miR-140-5p–mRNA regulatory network using Gephi software (release 0.8.1- β , http://gephi.github.io/).

Screening target genes and signaling pathways inhibited by miR-140-5p in published studies

To obtain downstream target genes and signaling pathways modulated by miR-140-5p in published studies, a comprehensive electronic search of Web of Science and PubMed databases was performed until April 20, 2017. The keyword 'miR-140-5p' in the titles or abstracts was used, and then, studies exploring the targets of miR-140-5p were collected.

Results

Mature sequences of miR-140-5p in various species

Mature sequences of miR-140-5p in various species were obtained in the miRBase database. The pre-miR-140-5p was located at position $69933081 \sim 69933180$ of chromosome 16, and the gene ID of human miR-140-5p was MIMAT0000431. As shown in Table 1, mature sequences of miR-140-5p were highly conserved in various species and human miR-140-5p was chosen for further analyses.

Table 1. Mature sequences of miR-140-5p in various species.

| ID | Mature name | Sequence |
|--------------|----------------|----------------------------|
| MIMAT0000151 | mmu-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0000431 | hsa-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0000573 | rno-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0001159 | gga-miR-140-5p | AGUGGUUUUACCCUAUG GUAG |
| MIMAT0001836 | dre-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0002143 | ssc-miR-140-5p | AGUGGUUUUACCCUAU GGUAG |
| MIMAT0006812 | oan-miR-140-5p | CAGUGGUUUUACCCUAU GGU |
| MIMAT0006197 | mml-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0012745 | mdo-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0012926 | eca-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0014557 | tgu-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0015763 | ppy-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0021765 | aca-miR-140-5p | CAGUGGUUUUACCCUA UGGU |
| MIMAT0022552 | ola-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0023767 | cgr-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0025434 | pol-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0026220 | ccr-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |
| MIMAT0032359 | ssa-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0035960 | chi-miR-140-5p | CAGUGGUUUUACCCUAU GGUAG |
| MIMAT0036560 | tch-miR-140-5p | CAGUGGUUUUACCCUAU GGUA |
| MIMAT0036719 | oha-miR-140-5p | CAGUGGUUUUACCCUA UGGUAG |

Prediction of target genes for miR-140-5p

As shown in Fig. 1, the number of predicted target genes of miR-140-5p in miRanda, TargetScan, RNAhybrid, and miRDB databases was 2370, 428, 1017, and 262, respectively. There were 482 target genes supported by at least two databases, 123 target genes predicted by at least three databases and five target genes supported by all four databases. The target genes of miR-140-5p predicted by at least three databases are listed in Table 2 and were used for further analyses.



Fig. 1. The number of predicted target genes of miR-140-5p.

GO enrichment analysis for predicted target genes of miR-140-5p

GO enrichment analysis was conducted for the target genes of miR-140-5p predicted by at least three databases. As shown in Table 3, the target genes of miR-140-5p were mainly located in basement membrane (P < 0.05) and participated in the molecular functions of protein binding, activating transcription factor binding, ion binding, lipid binding, and so on (P < 0.05). In addition, the target genes of miR-140-5p were involved in various biological processes, including biological regulation, metabolic process, cell communication, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathway (P < 0.05). Fig. 2 presents the number of target genes corresponding to each GO term.

KEGG pathway analysis for predicted target genes of miR-140-5p

Enriched signaling pathways for the target genes of miR-140-5p identified by KEGG pathway analysis were ranked according to the *P*-values. As shown in Table 4, the top rankings were related to Notch, cancer-associated pathway, TGF-beta, PI3K/Akt, HTLV infection, Hippo, HIF-1, alcoholism signaling pathways, and so on (P < 0.05); among them, Notch, TGF-beta, PI3K/Akt, and Hippo signaling pathways were well known to be associated with the pathogenesis of PAH. Fig. 3 presents the rich factor, Q value, and gene number corresponding to each pathway term.

| ABCA1 | ACSL6 | ADAM10 | ADAMTS5 | ADCY6 | ANKFY1 |
|----------|---------|----------|-------------|----------|---------|
| ANKIB1 | AP2B1 | BACH1 | BAZ2B | BCL9 | BMP2 |
| C1R | CADM3 | CAND1 | CAPN1 | CCNYL1 | CELF1 |
| CORO2A | CREB | CTCF | CYTH2 | DNM3 | DOK4 |
| DPP10 | DPYSL2 | EGR2 | EIF4G2 | ELAVL2 | ENTPD5 |
| EPB41L2 | ERC2 | FAM175B | FBN1 | FCHO2 | FES |
| FGF9 | FLRT2 | FOXP2 | FYCO1 | GNG5 | GIT1 |
| HAND2 | HDAC4 | HDAC7 | HDGFRP3 | HNRNPH3 | HS2ST1 |
| HSPA13 | IGSF3 | IPO7 | JAG1 | KAT2B | KBTBD2 |
| KIF1B | KLF6 | KLF9 | KLK10 | LAMC1 | LHFPL2 |
| LMNB1 | LPHN2 | LRAT | LRP4 | LSM14B | LYSMD3 |
| MARK1 | MED13 | MMD | MYCBP2 | MYO10 | NAA20 |
| NAALADL2 | NCKAP1 | NCOA1 | NCSTN | NFE2L2 | NLK |
| NPL | NUCKS1 | OSBPL6 | PPPICC | PAFAH1B2 | PDGFRA |
| PPTC7 | PDE7A | PPP1R12A | PALM2-AKAP2 | RBM39 | RFX7 |
| RNF19A | RALA | RAB10 | SEPT2 | STRADB | SYS1 |
| SLAIN1 | SAMD4 | SMOC2 | SNX2 | SRCAP | SHROOM3 |
| SIAH1 | SLC30A5 | SLC38A2 | TTYH3 ST5 | TLR4 | TTK |
| TJP1 | TSSK2 | TSPAN12 | TSC22D2 | TTYH2 | TGFBR1 |
| UBR5 | UBR5 | VEZF1 | VEGFA | WNT1 | WDFY3 |
| YOD1 | ZBTB10 | ZNF800 | | | |

Table 3. Gene ontology (GO) analysis for predicted target genes of miR-140-5p

| | T | | |
|--------------------|---|----------|--|
| | lerm | P-value | Genes annotated to the term |
| Biological proces | Ses | | |
| GO:0050794 | Regulation of cellular process | 5.39E-06 | VEGFA FGF9 PPP1CC Pin1 HDAC7 PDGFRA TGFBR1 ADAM10 |
| GO:0050789 | Regulation of biological process | 9.05E-06 | FGF9 BMP2 LAMC1 NUMBL PDGFRA PPP1CC ADAM10 TLR4 TGFB R1 |
| GO:0007154 | Cell communication | 5.69E-05 | WNT1 PPP1CC PDGFRA TLR4 HDAC7 ADAM10 BMP2 TGFBR1 |
| GO:0023052 | Signaling | 6.14E-05 | PDGFRA PPP1CC FGF9 WNT1 TGFBR1 BMP2 ADAM10 JAG1 TLR4 |
| GO:0044763 | Single-organism cellular process | 8.73E-05 | VEGFA FGF9 LAMC1 BMP2 TLR4 WNT1 TGFBR1 PDGFRA PPP1CC |
| GO:0065007 | Biological regulation | 9.89E-05 | VEGFA BMP2 TLR4 CREB PPP1CC PDGFRA ADAM10 TGFBR1 |
| GO:0007165 | Signal transduction | 0.00011 | PPP1CC PDGFRA WNT1 TGFBR1 FGF9 VEGFA NCSTN TLR4 ADAM 10 |
| GO:0042221 | Response to chemical stimulus | 0.00048 | NUMBL PPP1CC PDGFRA VEGFA LAMC1 TGFBR1 FGF9 BMP2 ADAM 10 TLR4 |
| GO:0072089 | Stem cell proliferation | 0.00087 | ACSL6 NUMBL RAB10 HAND2 WNT1 BMP2 |
| GO:0007166 | Cell surface receptor signaling pathway | 0.00370 | TLR4 WNT1 BMP2 ADAM10 NCSTN JAG1 PPP1CC PDGFRA FGF9 |
| GO:0050896 | Response to stimulus | 0.01555 | PPP1CC PDGFRA WNT1 CREB TGFBR1 VEGFA FGF9 BMP2 ADAM10 TLR4 |
| GO:0019538 | Protein metabolic process | 0.02054 | CREB PPP1CC PDGFRA NUMBL TLR4 ADAM10 BMP2 KAT2B NCSTN TGFBR1 |
| GO:0006464 | Cellular protein modification process | 0.03073 | HDAC4 CREB ADAM10 TLR4 TGFBR1 PPP1CC PDGFRA |
| Molecular function | ons | | |
| GO:0005515 | Protein binding | 2.53E-07 | TLR4 ADAM10 PDGFRA WNT1 HDAC7 VEGFA CREB PPP1CC TGFBR1 FGF9 |
| GO:0005488 | Binding | 0.00048 | HDAC7 JAG LMNB1 PDGFRA ADAM10 TLR4 FGF9 KAT2B TGFBR1 |
| GO:0033613 | Activating transcription factor binding | 0.00320 | EGR2 NFE2L2 HDAC4 HDAC7 HAND2 |
| GO:0043167 | lon binding | 0.00724 | VEGFA PPP1CC ADAM10 PDGFRA TGFBR1 HDAC4 FGF9 HDAC7 |
| GO:0008289 | Lipid binding | 0.04471 | LAMC1 OSBPL6 FES DNM3 MYO10 TLR4 |
| Cellular compone | ents | | |
| GO:0005604 | Basement membrane | 0.04119 | FGF9 PDGFRA TLR4 VEGFA SMOC2 |



Enriched GO Term (target gene)

Fig. 2. Gene ontology (GO) enrichment analysis for predicted target genes of miR-140-5p.

Prediction of upstream TFs for miR-140-5p and construction of TF-miR-140-5p-mRNA network

The number of predicted TFs for miR-140-5p with *P*-value <0.0001 was 393. To reduce false-positive results, TFs with a quality score (Q-score) less than 10 were filtered. As shown in Table 5, the remaining TFs, including PAX5, FOXI1, IRF1, FOSL1, RUNX2, were chosen for further analyses. Finally, by merging the regulatory relationships between TFs and miR-140-5p, miR-140-5p and target genes, as well as genes

and genes, we built a comprehensive TF-miR-140-5p-mRNA regulatory network, as shown in Fig. 4.

Screening target genes and signaling pathways modulated by miR-140-5p in published studies

A comprehensive electronic search of Web of Science and PubMed databases was performed until April 20, 2017, to obtain target genes and signaling pathways modulated by miR-140-5p in published studies.

| Table 4. K | voto Encyclopedia of | Genes and Genome | (KEGG) pathway | analysis for r | predicted target | genes of miR-140-5p. |
|------------|----------------------|------------------|-------------------|----------------|------------------|------------------------|
| | yoto Eneyolopoulu or | | (ICEOO) patinitay | analyoid for p | sioulotou turgot | gonoo or mint i to op. |

| Term | ID | Sample number | Background number | <i>P</i> -value | Genes |
|---|----------|------------------|----------------------|-----------------|---|
| Notch signaling pathway | hsa04330 | 4 | 52 | 0.006408 | JAG1 ADAM10 KAT2B NCSTN |
| Pathways in cancer | hsa05200 | 9 | 337 | 0.016384 | FGF9 TGFBR1 VEGFA SLC2A1 WNT1 BMP2 PDGFRA LAMC1 |
| Endocrine and other factor- regulated calcium reabsorption | hsa04961 | 3 | 48 | 0.022347 | AP2B1 ADCY6 DNM3 |
| HTLV-I infection | hsa05166 | 7 | 268 | 0.031935 | TGFBR1 KAT2B SLC2A1 EGR2 WNT1 PDGFRA ADCY6 |
| Regulation of actin cytoskeleton | hsa04810 | 6 | 221 | 0.031935 | PPP1R12A NCKAP1 FGF9 GIT1 PDGFRA PPP1CC |
| Pancreatic cancer | hsa05212 | 3 | 66 | 0.031935 | RALA TGFBR1 VEGFA |
| Epithelial cell signaling in Helicobacter pylori infection | hsa05120 | 3 | 66 | 0.031935 | TJP1 GIT1 ADAM10 |
| Proteoglycans in cancer | hsa05205 | 6 | 231 | 0.033735 | PPP1R12A FGF9 VEGFA WNT1 TLR4 PPP1CC |
| Adherence junction | hsa04520 | 3 | 74 | 0.037848 | NLK TJP1 TGFBR1 |
| Alcoholism | hsa05034 | 5 | 183 | 0.038681 | HDAC7 HDAC4 CREB3L1 GNG5 PPP1CC |
| PI3K-Akt signaling pathway | hsa04151 | 7 | 358 | 0.045545 | FGF9 VEGFA PDGFRA LAMC1 TLR4 CREB GNG5 |
| Focal adhesion | hsa04510 | 5 | 214 | 0.045545 | PPP1R12A VEGFA PDGFRA LAMC1 PPP1CC |
| Endocytosis | hsa04144 | 5 | 212 | 0.045545 | AP2B1 TGFBR1 GIT1 PDGFRA DNM3 |
| Viral carcinogenesis | hsa05203 | 5 | 213 | 0.045545 | HDAC7 HDAC4 KAT2B EGR2 CREB3L1 |
| Hepatitis B | hsa05161 | 4 | 151 | 0.045545 | TGFBR1 EGR2 TLR4 CREB3L1 |
| Insulin secretion | hsa04911 | 3 | 92 | 0.045545 | SLC2A1 CREB3L1 ADCY6 |
| GABAergic synapse | hsa04727 | 3 | 89 | 0.045545 | SLC38A2 GNG5 ADCY6 |
| TGF-beta signaling pathway | hsa04350 | 3 | 83 | 0.045545 | TGFBR1 SMAD4 BMP2 |
| Gap junction | hsa04540 | 3 | 96 | 0.045545 | TJP1 PDGFRA ADCY6 |
| Hippo signaling pathway | hsa04390 | 4 | 156 | 0.045565 | TGFBR1 WNT1 BMP2 PPP1CC |



Fig. 3. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis for predicted target genes of miR-140-5p.

| Table 5. | Prediction | of trar | scription | factors | and | binding | sites | of | miR-1 | 40-5p |) |
|----------|------------|---------|-----------|---------|-----|---------|-------|----|-------|-------|---|
|----------|------------|---------|-----------|---------|-----|---------|-------|----|-------|-------|---|

| Model ID | Model name | Hit position | Strand | Score | Predicted site sequence | |
|----------|------------|--------------|--------|---------|-------------------------|--|
| MA0014.2 | PAX5 | 95 | _ | 10.5663 | gtctcactctgttgcccat | |
| MA0014.2 | PAX5 | 3874 | _ | 11.6915 | gtcttgctctgttgcccag | |
| MA0025.1 | NFIL3 | 722 | _ | 10.0393 | TTCTTACATAA | |
| MA0035.3 | Gata1 | 3391 | _ | 10.0718 | acagataaaaa | |
| MA0036.2 | GATA2 | 3391 | _ | 10.4087 | acagataaaaattt | |
| MA0041.1 | Foxd3 | 4529 | + | 10.4011 | ttttgtttgttt | |
| MA0042.1 | FOXI1 | 984 | + | 11.5926 | GGATGTTTGTTT | |
| MA0042.1 | FOXI1 | 4529 | + | 10.3990 | ttttgtttgttt | |
| MA0046.1 | HNF1A | 4949 | + | 10.3282 | agttaataatttta | |
| MA0050.2 | IRF1 | 3825 | + | 11.0065 | tttttcttttcttttctttc | |
| MA0050.2 | IRF1 | 3840 | + | 12.4803 | tctttctttcttttttttttt | |
| MA0050.2 | IRF1 | 3844 | + | 10.0776 | tctttcttttttttttttttt | |
| MA0062.2 | GABPA | 1506 | + | 10.0387 | ccggaagtcga | |
| MA0073.1 | RREB1 | 1164 | _ | 10.9028 | TTTTGGTTGTTGTTTTGTTT | |
| MA0073.1 | RREB1 | 3734 | + | 10.2056 | саасаааасаааасааааса | |
| MA0471.1 | E2F6 | 143 | _ | 10.6410 | tcttcccgcct | |
| MA0477.1 | FOSL1 | 4238 | _ | 11.2229 | cctgagtcacc | |
| MA0478.1 | FOSL2 | 4239 | _ | 10.3145 | ctgagtcacct | |
| MA0481.1 | FOXP1 | 3756 | + | 10.2195 | асаааааааасасаа | |
| MA0481.1 | FOXP1 | 4018 | _ | 10.3465 | ttttgttttttagt | |
| MA0490.1 | JUNB | 4239 | _ | 10.6046 | ctgagtcacct | |
| MA0491.1 | JUND | 2362 | + | 10.0256 | GAAAATGATATCACA | |
| MA0493.1 | Klf1 | 4812 | + | 10.548 | сассасассса | |
| MA0511.1 | RUNX2 | 3813 | + | 11.453 | tgtgtatgtggtttt | |
| MA0515.1 | Sox6 | 3772 | _ | 10.2529 | gaaacaatgg | |
| MA0595.1 | SREBF1 | 2000 | - | 10.1772 | gtggcgtgat | |

Finally, a total of 26 papers including 23 target genes and seven signaling pathways inhibited by miR-140-5p were obtained; most of them focus on the functions of miR-140-5p suppressing tumor growth, migration, and invasion in various tumor tissues and cells. Two recent studies have found that SMURF1 and Dumt1 are direct target genes of miR-140-5p in pulmonary arterial smooth muscle cells (PASMCs) and are involved in the pathogenesis of PAH. The details are shown in Table 6.

Discussion

Pulmonary arterial hypertension is a chronic life-threatening condition requiring long-term management [13], and its available therapies are limited [6]. There is a clear and urgent need for new therapeutic options based on deeply exploring the pathogenesis of PAH. Previous studies have indicated that miR-140-5p is dramatically downregulated, which in turn causes the development of a variety of cancers by the loss of suppressing tumor cell migration and growth [14–17]. miR-140-5p has been recently found to be reduced in both PAH patients and MCT-induced PAH models in rat [11,12]. However, the downstream targets regulated by miR-140-5p contributing to the development of PAH remain largely unknown.

In this study, we found that the target genes of miR-140-5p were enriched in many biological processes, such as biological regulation, metabolic process, cell communication, signal transduction, response to chemical stimulus, stem cell proliferation, cell surface receptor signaling pathway. In KEGG pathway analysis, the target genes of miR-140-5p were mainly located in Notch, TGF-beta, PI3K/Akt, and Hippo signaling pathways. According to the TF-miRNAmRNA network, the important genes potentially regulated by miR-140-5p included PPI, TGF-betaR1, smad4, JAG1, ADAM10, FGF9, PDGFRA, VEGFA, TLR4, LAMC1, CREB, and the upstream TFs, which might regulate miR-140-5p expression including TAX5, FOXI, IRF1, GATA6, RUNX2. After thoroughly reviewing published literature, we found that 23 target genes and seven signaling pathways were truly inhibited by miR-140-5p in various tissues or cells; most of these downstream targets were in accordance with our present prediction.

Several studies have shown that activation of Notch3 pathway is involved in the pathogenesis of PAH [18,19]. We have previously shown that



Fig. 4. Regulatory network of TF-miR-140-5p-mRNA.

activation of Notch3 promotes PASMC proliferation and inhibition of Notch3 pathway prevents monocrotaline-induced development of PAH in rat [20,21]. JAG1 and ADAM10 are indispensable components of Notch signaling pathway, which were predicted as downstream targets of miR-140-5p in our analysis, suggesting that lack of miR-140-5p might promote the development of PAH by upregulation of JAG1 and ADAM10 genes and therefore activation of Notch3 cascade. In addition, activation of TGF-beta1/Smad4 signaling promotes a proliferative PASMC phenotype and induces PAH in rat [22,23]. We found that TGFbetaR1 and smad4 were possible downstream targets of miR-140-5p, reduction in miR-140-5p in PAH might stimulate TGF-beta1/Smad4 pathway by upregulating TGF-betaR1 and smad4. Previous studies have demonstrated that PDGF, TLR4, VEGFA, and FGF contribute to the pathogenesis of PAH via activating various signaling pathways, especially PI3K/Akt cascade [24–28]. CREB, an important transcription factor lying downstream of PI3K/Akt pathway, mediates the partial functions of PI3K/Akt [29]. In our analysis, PDGF, TLR4, VEGFA, FGF, and CREB were positively predicted as downstream targets of miR-140-5p, implying that miR-140-5p negatively regulates the functions of PI3K/Akt cascade by targeting FGF9, PDGFRA, VEGFA, TLR4, or CREB gene. Recent studies have also shown that Hippo signaling is associated with the development of PAH, which can be activated by PPI [30,31]. Our present results suggested that PPI was a direct target gene of miR-140-5p and might mediate miR-140-5p regulation of Hippo signaling.

Our predicted network provided potential target genes and relevant signaling pathways that might be modulated by miR-140-5p contribution to the **Table 6.** Target genes and signaling pathways modulated by miR-140-5p in published studies. NA, not available; HCC, hepatocellular carcinoma; T-ALL, T-cell acute lymphoblastic leukemia; Th1, T helper type 1; HSCC, hypopharyngeal squamous cell carcinoma; EPCs, endothelial progenitor cells; PH, pulmonary hypertension; HUVECs, human umbilical vein endothelial cells; BTC, biliary tract cancer; TSPCs, tendon stem/progenitor cells; LLC, Lewis lung cancer cells; MSCs, mesenchymal stem cells; TSCC, tongue squamous cell carcinoma.

| Author (Year) | Target genes | Inhibited pathways | Associated functions | Cell or tissue types |
|----------------|----------------------------|---------------------------------------|--|--|
| Hu (2017) | VEGFA | NA | Inhibit cell proliferation and invasion, promote apoptosis | Glioma tissues and cells |
| Meng (2017) | HMGN5 | NA | Decrease cell resistance to chemotherapy | Osteosarcoma tissues and cells |
| Yan (2017) | Pin1 | Pin1-dependent cancer pathway | Suppress tumor growth | HCC tissues and cells |
| Correia (2016) | TAL1 | NA | Suppress tumor growth | T-ALL cells |
| Guan (2016) | STAT1 | NA | Suppress Th1 cell differentiation | Th1 cells |
| Jing (2016) | ADAM10 | Notch1 signaling pathway | Suppress tumor migration and invasion | HSCC tissues and cells |
| Liu (2016) | HDAC7 | NA | Protect EPCs | EPCs |
| Lv (2016) | Slug | NA | Inhibit cell migration and invasion | HCC tissues |
| Rothman (2016) | SMURF1 | BMP signaling pathway | Inhibit cell proliferation, migration, and PH development | PASMCs, rat PH models |
| Su (2016) | IGF2BP1 | NA | Decrease cell proliferation, migration, and invasion | Cervical cancer cells and tissues |
| SUN (2016) | VEGFA | NA | Decrease cell proliferation, migration, and tube formation | HUVECs |
| Wei (2016) | IP3k2 | IP3 signaling pathway | Promote chemotherapy-induced autophagy | Human osteosarcoma cells |
| Yu (2016) | Septin 2 | NA | Suppress cell proliferation and colony formation | BTC tissues and cells |
| Zhang (2016) | Dnmt1 | NA | Inhibit cell proliferation, promote cell apoptosis | Human PH tissues, human PASMCs |
| Barter (2015) | FZD6 | Wnt signaling pathway | Promote chondrogenic differentiation | Mesenchymal stem cells |
| Chen (2015) | Pin1 | NA | Promote cell senescence | TSPCs |
| Lan (2015) | PDGFRA | NA | Inhibit cancer growth | Human ovarian cancer tissues and cells |
| Zhai (2015) | Smad2 | TGF-β signaling pathway | Decrease cell invasion and proliferation | Colorectal cancer stem cells |
| Zhang (2015) | VEGFA | NA | Inhibit tumor progression | Colorectal cancer tissues and cells |
| Zhang (2015) | TGFBR1 | TGF-β signaling pathway | Regulate adipocyte differentiation | Bone marrow stromal cells |
| Li (2014) | MMD | ERK signaling pathway | Inhibit cell proliferation | LLCs |
| Hwang (2014) | BMP2 | BMP signaling | Suppress osteogenesis | Human MSCs |
| Karlsen (2014) | RALA | NA | Stimulate chondrogenesis | MSCs |
| Yang (2014) | ADAM10, LAMC1, HDAC7 | NA | Suppress migration and invasion | TSCC tissues and cells |
| Shi (2013) | FoxP2 | NA | Impair dendritic development and vocal learning | Zebra finch brain tissues |
| Yang (2013) | TGFBR1, FGF9 | TGF-β and ERK signaling pathway | Suppress cell proliferation and tumor metastasis | HCC tissues and cells |

development of PAH. Several targets and pathways predicted in our analysis, such as TGF-betaR1, ADAM10, FGF9, PDGFRA, VEGFA and Notch, PI3K/Akt, TGF-beta cascades, have been demonstrated to mediate the effects of miR-140-5p on antiproliferation and prodifferentiation in several cell types in published studies [16,17,32,33]. While the other targets predicted in our study, including PPI, smad4, JAG1, LAMC1, TLR4, and CREB as well as Hippo signaling pathway, have not been confirmed in

the published literature, they still need further verification *in vivo* and *in vitro*.

Acknowledgement

This work was supported by Chinese National Science Foundation (No. 81670051 and No. 81330002).

Author contributions

ML and FL designed the study; WS, YW, LC, and QW analyzed and interpreted the data; WF, XY, QZ, and JW organized the results; FL wrote the manuscript.

References

- Grant JS, White K, MacLean MR and Baker AH (2013) MicroRNAs in pulmonary arterial remodeling. *Cell Mol Life Sci* 70, 4479–4494.
- 2 Higasa K, Ogawa A, Terao C, Shimizu M, Kosugi S, Yamada R, Date H, Matsubara H and Matsuda F (2017) A burden of rare variants in BMPR2 and KCNK3 contributes to a risk of familial pulmonary arterial hypertension. *BMC Pulm Med* **17**, 57.
- 3 Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S and Bonnet S (2013) Signal transduction in the development of pulmonary arterial hypertension. *Pulm Circ* **3**, 278–293.
- 4 Rabinovitch M (2012) Molecular pathogenesis of pulmonary arterial hypertension. *J Clin Invest* 122, 4306–4313.
- 5 Vaillancourt M, Ruffenach G, Meloche J and Bonnet S (2015) Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. *Can J Cardiol* **31**, 407–415.
- 6 McLaughlin VV (2011) Looking to the future: a new decade of pulmonary arterial hypertension therapy. *Eur Respir Rev* **20**, 262–269.
- 7 Negi V and Chan SY (2017) Discerning functional hierarchies of microRNAs in pulmonary hypertension. *JCI Insight* 2, e91327.
- 8 Bienertova-Vasku J, Novak J and Vasku A (2015) MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. *J Am Soc Hypertens* 9, 221–234.
- 9 Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, Maus UA, Nickel N, Haverich A, Hoeper MM, Golpon HA *et al.* (2012) Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. *J Heart Lung Transplant* **31**, 764–772.
- 10 Caruso P, MacLean MR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, Greig JA, Robertson

KE, Masson R *et al.* (2010) Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. *Arterioscler Thromb Vasc Biol* **30**, 716–723.

- 11 Rothman AM, Arnold ND, Pickworth JA, Iremonger J, Ciuclan L, Allen RM, Guth-Gundel S, Southwood M, Morrell NW, Thomas M *et al.* (2016) MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. *J Clin Invest* **126**, 2495–2508.
- 12 Zhang Y and Xu J (2016) MiR-140-5p regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation, apoptosis and differentiation by targeting Dnmt1 and promoting SOD2 expression. *Biochem Biophys Res Commun* 473, 342–348.
- 13 Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F *et al.* (2014) Definitions and diagnosis of pulmonary hypertension. *Turk Kardiyol Dern Ars* 42 (Suppl 1), 55–66.
- 14 Kai Y, Peng W, Ling W, Jiebing H and Zhuan B (2014) Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells. *Biochem Biophys Res Commun* 448, 308–314.
- 15 Li W and He F (2014) Monocyte to macrophage differentiation-associated (MMD) targeted by miR-140-5p regulates tumor growth in non-small cell lung cancer. *Biochem Biophys Res Commun* **450**, 844–850.
- 16 Yang H, Fang F, Chang R and Yang L (2013) MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. *Hepatology* 58, 205–217.
- 17 Jing P, Sa N, Liu X, Liu X and Xu W (2016) MicroR-140-5p suppresses tumor cell migration and invasion by targeting ADAM10-mediated Notch1 signaling pathway in hypopharyngeal squamous cell carcinoma. *Exp Mol Pathol* 100, 132–138.
- 18 Yu YR, Mao L, Piantadosi CA and Gunn MD (2013) CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. *Am J Respir Cell Mol Biol* 48, 647–654.
- 19 Xia Y, Bhattacharyya A, Roszell EE, Sandig M and Mequanint K (2012) The role of endothelial cell-bound Jagged1 in Notch3-induced human coronary artery smooth muscle cell differentiation. *Biomaterials* 33, 2462–2472.
- 20 Zhang Y, Xie X, Zhu Y, Liu L, Feng W, Pan Y, Zhai C, Ke R, Li S, Song Y *et al.* (2015) Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension. *Exp Lung Res* 41, 435–443.
- 21 Song Y, Zhang Y, Jiang H, Zhu Y, Liu L, Feng W, Yang L, Wang Y and Li M (2015) Activation of Notch3 promotes pulmonary arterial smooth muscle

cells proliferation via Hes1/p27Kip1 signaling pathway. *FEBS Open Bio* **5**, 656–660.

- 22 Aschner Y and Downey GP (2016) Transforming growth factor-beta: master regulator of the respiratory system in health and disease. *Am J Respir Cell Mol Biol* 54, 647–655.
- 23 Chai SD, Liu T, Dong MF, Li ZK, Tang PZ, Wang JT and Ma SJ (2016) Inactivated Pseudomonas aeruginosa inhibits hypoxia-induced pulmonary hypertension by preventing TGF-beta1/Smad signaling. *Braz J Med Biol Res* 49, e5526.
- 24 Bauer EM, Chanthaphavong RS, Sodhi CP, Hackam DJ, Billiar TR and Bauer PM (2014) Genetic deletion of toll-like receptor 4 on platelets attenuates experimental pulmonary hypertension. *Circ Res* 114, 1596–1600.
- 25 Sun Z (2014) Platelet TLR4: a critical link in pulmonary arterial hypertension. *Circ Res* 114, 1551– 1553.
- 26 Song Y, Wu Y, Su X, Zhu Y, Liu L, Pan Y, Zhu B, Yang L, Gao L and Li M (2016) Activation of AMPK inhibits PDGF-induced pulmonary arterial smooth muscle cells proliferation and its potential mechanisms. *Pharmacol Res* 107, 117–124.
- 27 Chuang JI, Huang JY, Tsai SJ, Sun HS, Yang SH, Chuang PC, Huang BM and Ching CH (2015) FGF9induced changes in cellular redox status and HO-1 upregulation are FGFR-dependent and proceed

- 28 Zheng Y, Ma H, Hu E, Huang Z, Cheng X and Xiong C (2015) Inhibition of FGFR signaling with PD173074 ameliorates monocrotaline-induced pulmonary arterial hypertension and rescues BMPR-II expression. J Cardiovasc Pharmacol 66, 504–514.
- 29 Garat CV, Crossno JT Jr, Sullivan TM, Reusch JE and Klemm DJ (2013) Inhibition of phosphatidylinositol 3kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cells. *J Cardiovasc Pharmacol* 62, 539–548.
- 30 Lv XB, Liu CY, Wang Z, Sun YP, Xiong Y, Lei QY and Guan KL (2015) PARD3 induces TAZ activation and cell growth by promoting LATS1 and PP1 interaction. *EMBO Rep* 16, 975–985.
- 31 Boucherat O, Bonnet S and Paulin R (2016) The HIPPO-thesis of pulmonary hypertension. Am J Respir Crit Care Med 194, 787–789.
- 32 Lan H, Chen W, He G and Yang S (2015) miR-140-5p inhibits ovarian cancer growth partially by repression of PDGFRA. *Biomed Pharmacother* **75**, 117–122.
- 33 Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G, Hou Y and Jiang P (2015) MicroRNA-140-5p inhibits the progression of colorectal cancer by targeting VEGFA. *Cell Physiol Biochem* 37, 1123–1133.